Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.
Journal article
2024-03-01T00:00:00+00:00
204
871 - 876
5
acute myeloid leukaemia, clinical trial, elderly, lenalidomide, low-dose cytosine arabinoside, Humans, Aged, Cytarabine, Lenalidomide, Remission Induction, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols